Deadline: 1 February, 1 June, 1 October each year
Open to: Outstanding young PhD students of biomedicine (max. age: 27 years)
Fellowship: Competitive monthly stipend
Description
The Boehringer Ingelheim Fonds awards PhD fellowships to outstanding junior scientists (max. age: 27 years) who wish to pursue an ambitious PhD project of approximately 3 years in basic biomedical research in an internationally leading laboratory. The peer-review-based selection process is highly competitive. Applicants should therefore be outstanding in all three selection criteria.
The purpose of the PhD Fellowship is to promote basic research in biomedicine by providing the best young, up-and-coming scientists with comprehensive support during their PhD phase.
Fellowship
The fellowship comprises a competitive monthly stipend that is initially granted for 2 years and that can be extended for up to another 12 months. Participation in international scientific conferences is also supported. In addition, fellowship holders are offered personal support, seminars to discuss their projects, communication training and alumni meetings, and thus can become part of a worldwide network. Read more under personal support and conditions.
Eligibility
The Boehringer Ingelheim Fonds (BIF) awards PhD fellowships to European citizens working in Europe or overseas, and to non-European citizens pursuing their PhD project in Europe. Applicants should not be older than 27 years at the respective deadline (1 February, 1 June, 1 October).
The PhD project must be experimental, in the field of basic biomedical research and aimed at elucidating basic biological phenomena of human life and acquiring new scientific knowledge. For a survey on the range of topics, please refer to FUTURA, the international journal of the foundation. Natural scientists should have been awarded their diploma, BSc, MSc or equivalent degree; physicians, veterinary surgeons and pharmacists should have passed their state examinations.
At the deadline, the applicant should not have been working on his/her project for more than 6 months. The beginning of the PhD project is considered by BIF to be:
- the date of the final examination (e.g. BSc, MSc, Diploma, DEA, Licenciatura, Laurea) on the official certificate if the applicant continues to work in the same research group; or
- the month of arrival at the laboratory in which the PhD project is pursued if the applicant changes his/her research group.
They do not support:
- applied research, such as biotechnological and pharmaceutical development and studies on the course of diseases or the treatment of symptoms;
- botanical and prokaryotic investigations unless they are of general biological importance;
- education, we can support only research. Fellowships therefore cannot be used during the course and rotation phase of PhD programmes, but only for the duration of the PhD project;
- the PhD fellowships cannot be used to supplement inadequate funding from other institutions or earned incomes, to bridge temporary financial difficulties or to complete investigations already sponsored by other institutions.
Application
The application for a PhD fellowship of the Boehringer Ingelheim Fonds consists of two parts:
- the online application sent by internet and
- two paper copies of the application including one CD to be sent by surface mail.
Both must be submitted by one of the respective deadlines of each year (date as per postmark for the paper version): 1 February, 1 June, 1 October
The entire application – including the project proposal – must be written in English and by the applicants themselves. However, we recommend consultation with the scientific supervisor. The form of the presentation should be adequate but simple; please do not staple, tack or bind documents.
The two paper copies should contain all the data and documents listed under (1) – (9). The CD, clearly labelled with applicant’s first name and family name should contain documents (1) – (7) preferably in one PDF or *.doc file. Please note, the foundation can process only PC files; Macintosh files therefore cannot be accepted.
Applicants can facilitate the selection process by adhering to the following sequence:
- Title and summary of PhD project (should not exceed one page);
- detailed presentation of PhD project (please also refer to “How to write a research proposal”): formulation of the problem, current status of research, applicant’s own groundwork, objectives, experimental strategy including methods of investigation, work schedule showing the anticipated duration of the entire project and the individual steps;
- reasons for wishing to work with a particular group;
- summary of diploma or equivalent thesis which should not exceed one page;
- list of applicant’s publications (if applicable);
- certificates of all academic and public examinations and certificates of vocational qualifications (including grades);
- photocopies of university entrance qualification or high school-leaving exam certificate, (e.g. Abitur, A-levels, Baccalaureat);
- letter of recommendation from the supervisor of the PhD thesis;
- letter of recommendation from the supervisor of the diploma or equivalent thesis (only if changing research group for the PhD project).
For more information please visit the FAQ section.
Contact:
Boehringer Ingelheim Fonds
Foundation for Basic Research in Medicine
Schlossmühle
Grabenstraße 46
55262 Heidesheim
Germany
tel. +49 (0)6132 8985 0
fax: +49 (0)6132 8985 11
secretariat(at)bifonds.de
This is a critical qusiteon that we as researchers deal on a daily basis. There are several ways to evaluate opportunities to gain cost and time efficiencies. A detailed assessment of the disease state, treatment options, product mechanism of action, clinical development plan with commercialization scope would give NPV/ reimbursement possibilities. Planning required studies and mapping regulatory requirements with detailed timelines is necessary. Opportunities to discuss with regulatory authorities would validate this plan. Study design with emphasis on patient type, sample size, study end-points, treatment duration, dose evaluations, etc should evaluate opportunities to collect these information for the specific demand of each study. All attempts to collect too much data should be avoided (Stick with study focus and demand). Opportunities for biomarkers should be evaluated early. Regular interactions with authorities may prevent surprises later (e.g. pediatric investigational plan, safety issues) and provide common understanding of result expectation. Strategy for study conduct (outsourcing or internal resourcing) early on would allow use of same vendors including CROs, central labs, pK, safety for multiple studies. This would allow faster implementation and build on experience of staff, lessons learnt, KOL experience, technology use, etc. Using detailed feasibilities in terms of KOL, country specific standard of care, comparator early in planning avoids amendments and opening sites/ countries as rescue. Feasibility tools with informatic tools like Citeline, other claims, emr data would provide specifics on physicians who treat, referral network patterns, etc. Contract, budget and IRB requirements would allow planning study schedules also. Studies using EDC early on would also give some cost efficiencies to allow savings on programming and other data management costs. Real opportunities are available with pivotal studies are through early planning of submission ready documents. Intergated submissions modules systems would allow parallel work to incorporate into BLA/ NDA all study reports, programs, eTMF, etc. Pharma needs to evaluate use of technology at every level to reduce redundancies from past submissions.